Robert F. Apple EVP, CFO and President of the Parenteral Products Division stated: “We are pleased that this product is now commercially available in the United States for children with growth hormone deficiency in a convenient, more user-friendly format and marks the first product launched under our strategic collaboration with Teva. We look forward to growing our business through additional product sales and royalty revenue with the launch of the Tjet device.”
